Wildy logo
(020) 7242 5778

Wildy’s Book News

Book News cover photo

Vol 21 No 9 Sept/Oct 2016

Book of the Month

Cover of Goode on Commercial Law

Goode on Commercial Law

Edited by: Ewan McKendrick
Price: £170.00

Pupillage & Student Offers

Special Discounts for Pupils, Newly Called & Students

Read More ...

Secondhand & Out of Print

Browse Secondhand Online


Pharmaceuticals, Biotechnology and the Law 3rd ed (eBook)

ISBN13: 9781405782630
Published: July 2016
Publisher: LexisNexis Butterworths
Country of Publication: UK
Format: eBook (ePub)
Price: £315.00 + £63.00 VAT
The amount of VAT charged may change depending on your location of use.

Once the order is confirmed you will be e-mailed a link from the publisher to download the eBook. This may take up to one working day. You will be asked to register your details with the publisher and agree to their terms and conditions.

All eBooks are supplied firm sale and cannot be returned. If you believe there is a fault with your eBook then contact us on ebooks@wildy.com and we will help in resolving the issue. This does not affect your statutory rights.

In stock.
Need help with ebook formats?

Also available as
+ £40.55 VAT

Pharmaceuticals Biotechnology and the Law is the definitive guide to the law in Europe relating to pharmaceuticals, biotechnology and their related areas such as medical devices.

Written by one of the country's leading patent and regulatory lawyers (Trevor Cook, Bird & Bird), this is the only text which comprehensively covers the wide variety of legal and regulatory issues which surround these industry sectors.

The new edition examines the background to, and the impact of, the law affecting this area. The text is primarily written from the perspective of European Community law, although in those relatively few areas where this is not harmonised it is written from the perspective of English law.

Intellectual Property Law, Medical Law, eBooks
Part I – Introduction and overview
Part II – Issues that arise when securing authorisation to market
Part III – Issues that arise after securing authorisation to market